Background Chlorogenic acid, a phenolic derivative, shows excellent pharmacological properties. However, poor lipidic solubility, permeability, and oral bioavailability restrict its clinical use. Therefore, two different…

Nanomedicines have emerged as a promising approach for targeted therapeutic delivery and specifically as a beneficial alternative to conventional cancer therapies as they can deliver higher concentrations of chemotherapeutic agents at the…

The REACH* addition of Triton™ X-100 to the candidate list of Substances of Very High Concern (SVHC), and its subsequent ban in Europe, left biopharmaceutical manufacturers seeking viable alternatives to this essential bioprocessing…

Create a future without cancer. The time to act is now. World Cancer Day takes place every year on 4 February and will be held for the 24rd time in 2024 under the theme "Close the Care Gap". The day was initiated as a global…

The FDA approved 50 novel drugs in 2021, including the first KRAS inhibitor for cancer and the first anti-amyloid antibody for Alzheimer’s disease. Article by Asher Mullard - Nature Reviews Drug Discovery - 04 January 2022 The FDA’s…

Ibrutinib (IBR) is the choice of drug for the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). IBR has low oral bioavailability of 2.9% owing to its high first pass metabolism. Present study was aimed to…